Search

• Written by: K. Hirano ×
• Journal or magazine: JTO Clinical and Research Reports ×
• Clear filters

1 result for “Reaction Department”

1. Medical study · Medical research · 2021

   Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

   …survival was 9.7 months. A total of 30 patients (96.8%) had at least one adverse event. Common treatment-related adverse events were infusion-related reaction (16.1%), hiccups (9.7%), and interstitial lung disease…